Last reviewed · How we verify
NCT06796621
Building Respectful Online Space (BROS): Evaluating a Co-designed Anti-cyberbullying Intervention Among Adolescents
NA trial testing Building Respectful Online Space (BROS) in Cyberbullying in 120 participants. Participants enrolled and being followed up; not accepting new ones.
29 May 2025
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 120 |
| Start date | 12 February 2025 |
| Primary completion | 29 May 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Building Respectful Online Space (BROS)
- Healthy diet education program
Conditions studied
- Cyberbullying — all drugs for Cyberbullying →
Sponsor
Chinese University of Hong Kong
Who can join
Adults 12 to 15, any sex, with Cyberbullying. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: The growing prevalence of cyberbullying throughout the world indicates the importance of anti-cyberbullying interventions, especially for adolescents. While few interventions target cyberbullying, content from different regions may not necessarily apply to local contexts, adolescents' viewpoints were not considered in the past designs, few local RCTs, and unclear sustainability. Objectives: To evaluate the feasibility, acceptability and preliminarily effects of the co-designed anti-cyberbullying intervention: Building Respectful Online Space (BROS). Methods: A sample of around 90 aged 12 to 15 will be recruited from secondary schools in Hong Kong. This study will adopt a 2-arm experimental trial. Each class will be randomly assigned equally into the intervention arm (BROS) and control arm (Heathy Diet), and eligible students will be allocated to either arm accordingly. The intervention will be provided in one or 3 days based on the school schedule. Participants will be assessed at baseline, 3 weeks later, and 12-week follow-up assessments. The primary outcome is cyberbullying behaviour of perpetration and victimisation; the secondary outcome includes cyberbullying attitudes, sleep quality, and psychosocial well-being. Feasibility and acceptability will be assessed. And generalised estimating equations analysis will be used to investigate the research objectives. Potential contributions: The results of this study will provide evidence-based support for using a blended approach to prevent cyberbullying, promote psychosocial well-being, and promote sleep health. This intervention is dedicated to using evidence-to-user-driven ideas to develop culturally sensitive interventions to effectively prevent cyberbullying in the future.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06796621
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06796621 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 5 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06796621.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing